Ratings Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
73.26 ^USD	+1.57%		+1.23%	+2.29%

Apr. 23	Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating	MT
Apr. 22	Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
INTRA-CELLULAR THERAPIES, INC.	+2.29%	7.72B	D+
CSL LIMITED	-4.66%	86.13B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B	A-
BIOGEN INC.	-19.27%	30.42B	B-
UCB	+57.86%	25.23B	A
INCYTE CORPORATION	-17.69%	11.6B	B-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B	B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B	D+
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B	B+
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes